Proteome Sciences PLC
28 March 2000
Not for release, publication or distribution in or into the United States
Proteome Sciences plc
Proposed placing of
3,777,775 New Ordinary Shares at 45p per share
to raise approximately £1.7 million
and
Proposed Open Offer
by
WestLB Panmure
of
10,199,636 New Ordinary Shares at 45p per share
to raise up to £4.4 million, net of expenses
Summary
- Proteome Sciences plc ('Proteome' or the 'Company') is raising approximately
£6.1 million net of expenses by way of a Placing and an Open Offer on the basis
of 1 for 8 at 45p. The Company is raising approximately £1.7 million through a
Placing and up to a further £4.6 million through an Open Offer. WestLB Panmure,
are brokers to the Open Offer.
- Under the Placing 3,777,775 New Ordinary Shares are being conditionally placed
subject to shareholder approval, with certain existing shareholders at a price
of 45p per share.
- Funds raised pursuant to the Placing will be used to:-
- continue and extend certain of the Company's proteomic research
programmes.
- to take the Company's research through to commercialisation.
- Under the Open Offer 10,199,636 New Ordinary Shares are being offered to
qualifying shareholders on a 1 for 8 basis at a price of 45p per share.
- Funds raised under the Open Offer in excess of £1.5 million will be
used to establish a small core proteomics facility in the UK.
The Record Date for the Open Offer is 20 March 2000 and the last time and date
for receipt of Application Forms is 3.00p.m. on 18 April 2000. Application
Forms are personal to shareholders and may not be transferred expect to satisfy
bona fide market claims.
As approximately 20 per cent of the issued ordinary share capital of Proteome
Sciences plc is held in the US, Qualifying Shareholders should note that they
are entitled to apply for New Ordinary Shares in excess of their maximum initial
pro rata entitlements.
For further information, please contact:
Proteome Sciences PLC Tel: 01932 865065
Christopher Pearce, Chief Executive Officer
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.